MARKET

ENZ

ENZ

Enzo Biochem Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

2.296
+0.086
+3.87%
Opening 10:15 05/27 EDT
OPEN
2.220
PREV CLOSE
2.210
HIGH
2.296
LOW
2.220
VOLUME
3.50K
TURNOVER
2.25K
52 WEEK HIGH
4.150
52 WEEK LOW
2.210
MARKET CAP
111.82M
P/E (TTM)
409.93
1D
5D
1M
3M
1Y
5Y
Investors in Enzo Biochem (NYSE:ENZ) have unfortunately lost 73% over the last five years
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Spare a thought for those who held...
Simply Wall St. · 05/09 15:57
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's session saw 211 companies set new 52-week lows.
Benzinga · 05/03 16:20
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 04/25 12:29
Enzo Biochem gains on New York approval for test to detect human papillomavirus
The shares of Enzo Biochem (NYSE:ENZ) have added ~9% in the pre-market Tuesday after the health services company announced that the New York State Department of Health (DOH) had approved its
Seekingalpha · 04/19 12:49
BRIEF-Enzo Biochem Announces New York State DOH Approval Of HPV Molecular Diagnostic Test
reuters.com · 04/19 12:11
Enzo Biochem Reports New York State Dept. Of Health Approval For Its Human Papillomavirus Molecular Diagnostic Test
Approval adds HPV to menu of tests available on Enzo’s GenFlex® platform, which includes COVID-19 PCR and CT/NG/TV NEW YORK, NY, April 19, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ)
Benzinga · 04/19 12:03
Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test
Approval adds HPV to menu of tests available on Enzo’s GenFlex® platform, which includes COVID-19 PCR and CT/NG/TVNEW YORK, NY, April 19, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnosti...
GlobeNewswire · 04/19 12:00
Enzo Biochem Wins New York State Approval of HPV Molecular Diagnostic Test
MT Newswires · 04/19 09:57
More
No Data
Learn about the latest financial forecast of ENZ. Analyze the recent business situations of Enzo Biochem Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ENZ stock price target is 5.50 with a high estimate of 5.50 and a low estimate of 5.50.
High5.50
Average5.50
Low5.50
Current 2.260
EPS
Actual
Estimate
-0.09-0.05-0.000.04
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q4 2019
Institutional Holdings
Institutions: 94
Institutional Holdings: 24.04M
% Owned: 49.35%
Shares Outstanding: 48.71M
TypeInstitutionsShares
Increased
13
1.10M
New
3
76.52K
Decreased
14
1.03M
Sold Out
10
242.93K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+1.74%
Healthcare Providers & Services
+1.46%
Key Executives
Chief Executive Officer/Director
Hamid Erfanian
Chief Financial Officer/Senior Vice President/Treasurer/Secretary
David Bench
Chief Operating Officer
Kara Cannon
Other
Dieter Schapfel
Lead Director/Independent Director
Mary Tagliaferri
Director
Elazar Rabbani
Independent Director
Bradley Radoff
Independent Director
Ian Walters
No Data
No Data
About ENZ
Enzo Biochem, Inc. (Enzo) is an integrated diagnostics, clinical lab, and life sciences company that is focused on delivering and applying advanced technology to produce reliable products and services for clinical needs. The Company develops, manufactures and sells technology solutions and platforms to clinical laboratories, specialty clinics, researchers and physicians globally. Enzo's segments include Enzo Clinical Lab, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Lab is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. Enzo Life Sciences manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. Enzo Therapeutics is a biopharmaceutical venture that developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.

Webull offers kinds of Enzo Biochem, Inc. stock information, including NYSE:ENZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENZ stock methods without spending real money on the virtual paper trading platform.